FIRSTPOST YOUSPEAK
Thursday, May 23rd 03:30 PM IST
Gallery
Ranbaxy Laboratories GALLERY.
Indian employees of the Ranbaxy Laboratories Limited pharmaceutical Indian factory leave work at the end of the day at Toansa village in Ropar about 50 Km from Chandigarh on May 14, 2013. The US subsidiary of New Delhi-based Ranbaxy Laboratories pleaded guilty to seven counts of felony after it distributed several India-produced adulterated generic drugs in the United States in 2005 and 2006. They were all made in a facility near Chandigarh city in northern India, which US Food and Drug Administration inspectors cited for poor record keeping and inadequate testing for the stability of the drugs over time. Indian employees of the Ranbaxy Lab
A view of the Ranbaxy Laboratories Limited pharmaceutical Indian factory at Toansa village in Ropar about 50 Km from Chandigarh on May 14, 2013. The US subsidiary of New Delhi-based Ranbaxy Laboratories pleaded guilty to seven counts of felony after it distributed several India-produced adulterated generic drugs in the United States in 2005 and 2006. They were all made in a facility near Chandigarh city in northern India, which US Food and Drug Administration inspectors cited for poor record keeping and inadequate testing for the stability of the drugs over time. A view of the Ranbaxy Laboratories
A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice. The settlement is its largest-ever with a generic drugmaker over drug safety, according to the U.S. government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims. A Ranbaxy office building is pictur
Ranbaxy-manufactured products are stacked on the counter as an Indian chemist talks on his mobile phone at his shop in New Delhi on May 14, 2013. US authorities announced Monday a 500 million dollar fine against Indian generic pharmaceutical manufacturer Ranbaxy after it pleaded guilty to selling adulterated drugs in the United States. Ranbaxy USA, the US subsidiary of Ranbaxy Laboratories Limited, based near New Delhi, pleaded guilty to seven counts of felony after it distributed several India-produced adulterated generic drugs in the US in 2005-2006. Ranbaxy-manufactured products are s
strongNew Delhi:/strong Drug major Ranbaxy Laboratories today reported a consolidated net loss of Rs 492.44 crore for the fourth quarter ending December 31, 2012, mainly on account of recall of its cholesterol lowering drug atorvastatin calcium tablets in the US market and currency fluctuation. The company had posted a consolidated net loss of Rs 2,982.76 crore during the corresponding quarter of previous fiscal. During the period under review, consolidated net sales of the company stood at Rs 2,670.80 crore as against Rs 3,752.01 crore for the same quarter last fiscal. [caption id=attachment_640748 align=alignleft width=380 strongNew Delhi:/strong Drug major
Drugmaker Ranbaxy Laboratories has voluntarily recalled its cholesterol-lowering drug atorvastatin in the United States, a development that could dent its image further in the world's biggest prescription drug market where the company faced an earlier ban. Ranbaxy did not specify the reason for the recall of the drug, which largely drove the company's sales in the first of half the year. Shares of the company fell more than 4 percent following the announcement. [caption id=attachment_533435 align=alignleft width=380 Drugmaker Ranbaxy Laboratories has
Drug major Ranbaxy Laboratories said it has received approval from Malaysian authorities to set up its second manufacturing plant in the country at an investment of $40 million (around Rs 220 crore). Ranbaxy Malaysia Sdn Bhd, a subsidiary of Ranbaxy Laboratories, received approval for setting up a greenfield manufacturing facility in Malaysia as an EPP (Entry Point Project), the company said in a statement. Ranbaxy will be investing around RM 125 Million ($ 40 million) in this project that will provide employment to over 200 people, it added. [caption id=attachment_454727 align=alignleft width=380 Drug major Ranbaxy Laboratories sai
Drug firm Ranbaxy Laboratories reported a consolidated net loss of Rs 580.14 crore for the second quarter ended June 30, 2012. The company had posted a net profit of Rs 245.53 crore during the same period of previous year, Ranbaxy Laboratories said in a filing to the BSE. [caption id=attachment_412356 align=alignleft width=380 Drug firm Ranbaxy Laboratories repo
The head of Indian drugmaker Ranbaxy Laboratories says he's charging ahead with plans to expand sales in the crucial US market, despite extra oversight from American regulators over quality questions that have blocked imports of 31 of its medicines. Ranbaxy, which almost exclusively makes generic pills, particularly is aiming to regularly be first on the US market with just-approved generic drugs, CEO Arun Sawhney said. [caption id=attachment_373469 align=alignleft width=380 The head of Indian drugmaker Ranbax